Financial Gravity Asset Management’s ImmunityBio IBRX Stock Holding History

Financial Gravity Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-52	Closed	-$287	–	1917
2024 Q1	$287	Buy	52 +48	+1,200%	+$217	﹤0.01%	1541
2023 Q4	$18	Buy	4 +2	+100%	+$6	﹤0.01%	1438
2023 Q3	$7	Sell	2 -1	-33%	-$2	﹤0.01%	1182
2023 Q2	$26	Buy	+3	New	+$8	﹤0.01%	1470
2023 Q1	–	Sell	-5	Closed	-$5	–	1381
2022 Q4	$5	Buy	+5	New	+$27	﹤0.01%	1383

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Financial Gravity Asset Management's IBRX Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 52 shares — an estimated $287 sold.

Financial Gravity Asset Management first reported a position in IBRX in Q4 2022 and held it in 5 quarters. The position peaked at $287 in Q1 2024. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

Financial Gravity Asset Management reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 52 ImmunityBio shares in Q2 2024, an estimated $287.
Financial Gravity Asset Management first reported a position in ImmunityBio in Q4 2022 and held it in 5 quarters.
Financial Gravity Asset Management's ImmunityBio position peaked at $287 in Q1 2024.
193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.